Replimune Group, Inc.

REPL trades with a stunning 51.35% short interest—more than half the float—creating significant squeeze potential if clinical trial momentum accelerates. The RSI of 75.8 signals overbought conditions, yet the biotech's micro-cap status ($0.4B) means explosive moves are routine here. With no trailing earnings (pre-revenue biotech), valuation metrics are meaningless; everything hinges on pipeline progress. The elevated short ratio combined with oversold technicals suggests either a crowded bearish bet ripe for covering or a warning sign the Street views the science skeptically. This setup screams volatility rather than fundamental clarity.